Literature DB >> 30427649

Endocrine Conditions in Older Adults: Menopause.

Jennifer Bain1, Scott Bragg2, Anita Ramsetty2, Sarah Bradford2.   

Abstract

Menopause is the cessation of menstruation due to loss of ovarian function and is diagnosed retrospectively after 12 consecutive months of amenorrhea. The average age of onset in the United States is 51 years but symptoms can be present for many years before and after. Vasomotor and genitourinary symptoms are the most common. Hormone replacement therapy (HRT) is the most effective management. Given the possible risks of cardiovascular disease and breast cancer, recommendations for HRT after the Women's Health Initiative study are to limit HRT to the lowest dose and shortest duration to relieve symptoms. Based on more recent data, women younger than 60 years and less than 10 years from menopause onset appear to be at lower risk of these factors when initiating HRT. Dosing, type of HRT, administration route, and duration of use are individualized. Selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, gabapentin, and clonidine are alternative nonhormonal options with high-quality evidence supporting their use for symptom relief. However, these management options are less effective than HRT. Local vaginal therapy is effective and recommended for management of isolated vulvovaginal symptoms. Decisions to discontinue HRT should be based on symptoms and risk factors, not age. Written permission from the American Academy of Family Physicians is required for reproduction of this material in whole or in part in any form or medium.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30427649

Source DB:  PubMed          Journal:  FP Essent        ISSN: 2159-3000


  1 in total

1.  Initial experience with HydroPearl microspheres for uterine artery embolization for the treatment of symptomatic uterine fibroids.

Authors:  Matthew A Patetta; Ari J Isaacson; Jessica K Stewart
Journal:  CVIR Endovasc       Date:  2021-03-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.